A vision for the future?

被引:7
作者
Baum, M [1 ]
机构
[1] UCL, Sch Med, Dept Psychooncol, Bland Sutton Inst, London W1P 7PL, England
关键词
adjuvant therapy; early breast cancer; anastrozole; ICI 182,780; goserelin; premenopausal; postmenopausal;
D O I
10.1054/bjoc.2001.1984
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Systemic adjuvant therapy is recommended immediately following surgical removal of the primary tumour in the majority of patients with early breast cancer, to prevent the recurrence of distant metastases. Significant progress has been made in the development and evaluation of endocrine therapies for systemic adjuvant therapy. In pre- and perimenopausal women, ovarian ablation has proven to be a valuable treatment option, though not always desirable for young patients. Thus, reversible medical ovarian suppression with a luteinizing hormone releasing hormone agonist, such as goserelin (Zoladex (TM)), may provide an attractive alternative for such patients. International trials have indicated that goserelin provides an important addition to the choice of adjuvant therapies now available to pre- and perimenopausal patients. For postmenopausal patients, it is hoped that the ATAC (Arimidex, tamoxifen, alone or in combination) trial will reveal whether or not the benefits of anastrozole (Arimidex (TM)) observed in advanced disease, where it has proven to be well tolerated and at least as effective as tamoxifen in recent trials, will translate to the early setting to provide further management options for these patients. On the horizon is yet another exciting endocrine agent, ICI 182,780 (Fulvestrant (TM)), which has also been shown to be as effective as anastrozole in advanced disease. In terms of the future, these agents are likely to provide additional valuable treatment choices for early breast cancer across the patient spectrum. (C) 2001 Cancer Research Campaign.
引用
收藏
页码:15 / 18
页数:4
相关论文
共 28 条
[11]   Tamoxifen for the prevention of breast cancer -: Pro [J].
Fisher, B .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (02) :142-145
[12]   Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors [J].
Fisher, B ;
Dignam, J ;
Bryant, J ;
DeCillis, A ;
Wickerham, DL ;
Wolmark, N ;
Costantino, J ;
Redmond, C ;
Fisher, ER ;
Bowman, DM ;
Deschenes, L ;
Dimitrov, NV ;
Margolese, RG ;
Robidoux, A ;
Shibata, H ;
Terz, J ;
Paterson, AHG ;
Feldman, MI ;
Farrar, W ;
Evans, J ;
Lickley, HL .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (21) :1529-1542
[13]   A RANDOMIZED CLINICAL-TRIAL EVALUATING TAMOXIFEN IN THE TREATMENT OF PATIENTS WITH NODE-NEGATIVE BREAST-CANCER WHO HAVE ESTROGEN-RECEPTOR POSITIVE TUMORS [J].
FISHER, B ;
COSTANTINO, J ;
REDMOND, C ;
POISSON, R ;
BOWMAN, D ;
COUTURE, J ;
DIMITROV, NV ;
WOLMARK, N ;
WICKERHAM, DL ;
FISHER, ER ;
MARGOLESE, R ;
ROBIDOUX, A ;
SHIBATA, H ;
TERZ, J ;
PATERSON, AHG ;
FELDMAN, MI ;
FARRAR, W ;
EVANS, J ;
LICKLEY, HL ;
KETNER, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (08) :479-484
[14]   Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer [J].
Goldhirsch, A ;
Glick, JH ;
Gelber, RD ;
Senn, HJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (21) :1601-1608
[15]  
HOUGHTON J, 2000, P AN M AM SOC CLIN, V19, pA93
[16]  
Jakesz R., 2001, Breast, V10, pS10
[17]   Luteinizing hormone-releasing hormone analogues the rationale for adjuvant use in premenopausal women with early breast cancer [J].
Jonat, W .
BRITISH JOURNAL OF CANCER, 1998, 78 (Suppl 4) :5-8
[18]  
JONAT W, 2000, P AN M AM SOC CLIN, V19, pA87
[19]   Antiestrogens: Mechanisms of action and resistance in breast cancer [J].
Katzenellenbogen, BS ;
Montano, MM ;
Ekena, K ;
Herman, ME ;
McInerney, EM .
BREAST CANCER RESEARCH AND TREATMENT, 1997, 44 (01) :23-38
[20]  
Kaufmann M., 2001, Breast, V10, pS30